Why Is Fatty-Liver Drug Developer Inventiva Stock Trading Higher On Monday?
Why Is Fatty-Liver Drug Developer Inventiva Stock Trading Higher On Monday?
Inventiva SA (NASDAQ:IVA) stock traded higher on Monday, with a strong session volume of 8.55 million compared to an average volume of 9.91k, according to data from Benzinga Pro.
Inventiva SA (纳斯达克：IVA) 股票周一交易上涨，成交量较高，为855万，而平均成交量为0.991万，根据Benzinga Pro的数据。
The company announced it has secured financing of immediately 94.1 million euros ($99.36 million) and up to 348 million euros ($379.55 million) to fund the completion of the Phase 3 NATiV3 MASH trial and preparation for the potential filing for marketing approval and commercialization of lanifibranor.
该公司宣布已获得立即9410万欧元（9936万美元）和最高34800万欧元（37955万美元）的融资，用于完成第3期NATiV3 MASH试验并为潜在的萝非布瑞诺(NATiV3)的营销批准以及商业化做准备。
The Transaction was led by New Enterprise Associates, BVF Partners LP, and Samsara BioCapital, with the participation of additional existing and new investors.
交易由新企业协会(New Enterprise Associates)、BVF Partners LP和Samsara BioCapital领导，其他现有和新投资者也参与其中。
Also Read: Why Is Inventiva's Stock Trading Higher on Monday?
阅读更多：为什么Inventiva的股票周一交易上涨？
Pursuant to the Transaction and subject to shareholder approval at the next general meeting to be convened by December 16, 2024, the company appointed Mark Pruzanski as Chairman and Srinivas Akkaraju as director.
根据交易并经股东在2024年12月16日召开的下次股东大会批准，公司任命Mark Pruzanski为董事长，Srinivas Akkaraju为董事。
Each of the other four largest investors is to name up to four additional directors, of whom at least two will qualify as independent and would replace existing directors (excluding Frederic Cren, Mark Pruzanski, and Srini Akkaraju).
其他四大股东将各自提名最多四名额外董事，其中至少两名需符合独立条件，并将取代现有董事（不包括Frederic Cren、Mark Pruzanski和Srini Akkaraju）。
The company also estimates that, before the Transaction, it would need approximately 250 million euros to finance its activities until the topline results from its NATiV3 trial, targeted for the second half of 2026.
公司还估计，在交易之前，需要大约25000万欧元来资助其活动，直到预计于2026年下半年公布其NATiV3试验的最终结果。
This estimate includes an estimated 130 million-135 million euros needed to finance the company's activities over the next 12 months mentioned above.
此估计包括用于在上述未来12个月内资助公司活动的约13000万-13500万欧元。
In February, Inventiva announced it stopped enrolling new patients in the NATiV3 Phase 3 trial for lanifibranor in non-alcoholic steatohepatitis (NASH) due to a reported serious adverse reaction. This reaction involved elevated liver enzymes in a patient undergoing treatment.
Inventiva在二月宣布，由于一名正在接受治疗的患者报告出现严重不良反应，停止了兰非布鲁诺在非酒精性脂肪肝（NASH）的第三阶段试验NATiV3的新患者注册。这种反应涉及患者肝酶升高。
In March, the company lifted the previously disclosed voluntary pause on screening and randomization of its NATiV3 clinical trial, and sites are resuming screening activities.
三月份，该公司解除了先前披露的对NATiV3临床试验筛选和随机化的自愿暂停，各研究中心正在恢复筛选活动。
Price Action: At last check on Monday, IVA stock was up 31.20% at $2.48.
股价表现：截至周一最后检查时，IVA股票上涨了31.20%，报2.48美元。
- Why Is Chronic Disease-Focused Jasper Therapeutics Stock Trading Higher On Monday?
- 为什么慢性疾病为重点的Jasper Therapeutics股票在星期一交易时走高？
